Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bazedoxifene -Treatment for Women With Schizophrenia
Sponsor: The Alfred
Summary
To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.
Official title: Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2019-10-07
Completion Date
2026-12-31
Last Updated
2026-06-03
Healthy Volunteers
No
Interventions
Bazedoxifene Acetate
Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
Placebo
Identically packaged placebo capsule daily
Locations (1)
Multidisciplinary Alfred Psychiatry Research Centre
Melbourne, Victoria, Australia